#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

#### For the month of June 2023

Commission File Number: 001-40086

Portage Biotech Inc. (Translation of registrant's name into English)

<u>N/A</u>

(Translation of registrant's name into English)

### <u>British Virgin Islands</u>

(Jurisdiction of incorporation or organization)

### <u>Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110</u> (Address of principal executive offices)

(riddress of principal executive offices)

#### c/o Portage Development Services Inc., Ian Walters, 203.221.7378 <u>61 Wilton Road, Westport, Connecticut 06880</u>

(Name, telephone, e-mail and/or facsimile number and Address of Company Contact Person)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: 🖂 Form 20-F 🛛 Form 40-F

### Exhibits

The following Exhibit is filed with this report:

Exhibit	Description
<u>99.1</u>	Corporate Presentation

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 20, 2023

### Portage Biotech, Inc.

By:
Name
Title:

Title:

/s/ Allan Shaw Allan Shaw Chief Financial Officer



**Corporate Presentation** 

Nasdaq: PRTG June 2023

1



This presentation is for information purposes only. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction. Such an offer can only be made by prospectus or other authorized offering document. This presentation and materials or fact of their distribution or communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever in relation thereto. No securities commission or similar authority in Canada, the United States or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained in this presentation.

### Forward-Looking Information

This presentation contains "forward-looking statements" that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the "Securities Act," and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," 'believe, "can," 'continue," 'could, "estimate," "expect," "intend," "may," 'plan," "project," 'seek," 'should," "strategy," 'target," 'will, "would' and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from iture results on those discussed in our reports filed with the Securities and Exchange Commission from time to time. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

No representation or warranty, express or implied, is or will be given by Portage Biotech Inc. (the "Company") or any of its affiliates, directors officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency of this presentation or for any errors, omissions, misstatements, negligent or otherwise, contained herein.

A shelf registration statement on Form F-3 relating to the public offering of the Company's common stock was declared effective by the Securities and Exchange Commission on March 8, 2021. Before you invest, you should read the prospectus in the registration statement and related preliminary prospectus supplement that the Company will file with the Securities and Exchange Commission for more complete information about the Company and the offering. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be available on the website of the Securities and Exchange Commission at www.sec.gov.



portage

Immuno-Oncology Company with Four First/Best in Class Compounds in the Clinic

Multiple Phase 1b/2 Data Catalysts in 2023 and 2024

Experienced Leadership Team from Bristol Myers Squibb

Cost-Efficient Business Model, Potential Runway to Achieve Multiple Inflection Points


Proven Leadership with Oncology and Financing Expertise





### Our Formula for Success





# Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value



	ASSET	INDICATION	STAGE	# of PTS	Interim Data	Final Data
	PORT-2	Melanoma + NSCLC	Phase 1	18	ASCO 2023	SITC 2023
	PORT-3	Solid Tumors	Phase 1	12		
0	PORT-2	Refractory Melanoma	Phase 2	10	ASCO 2024	SITC 2024
2	PORT-2+ Keytruda®	Front line PD-L1 + NSCLC	Phase 2	30	SITC 2024	ASCO 2025
6	PORT-2+ Keytru da <sup>®</sup>	PD-L1 - NSCLC 2 <sup>nd</sup> /3 <sup>rd</sup> line	Phase 2	10	ASCO 2024	SITC 2024
4	PORT-2+ Keytruda®	PD-L1 + NSCLC 2 <sup>nd</sup> line	Phase 2	15	ASCO 2024	SITC 2025
	ASSET	INDICATION	STAGE	# of PTS	Interim Data	Final Data
	PORT-6 (A2A)	A2A exp Solid Turnors	Phase 1a	21-27	ASCO-GU 24	SITC 2024
	PORT-7 (A2B)	A2B exp Solid Tumors	Phase 1a	18	ASCO 2024	SITC 2024
5	PORT-6 (A2A)	A2B exp Solid Tumors	Phase 1b	20	SITC 2024	SITC 2025
6	PORT-7 (A2B)	A2A exp Solid Tumors	Phase 1b	20	SITC 2025	ASCO 2026
7	PORT-6 (A2A) + CPI	A2A exp Solid Tumors	Phase 1b	20	SITC 2024	SITC 2025
		A2B exp Solid Tumors	Phase 1b	20	SITC 2025	ASCO 2026
8	PORT-7 (A2B) + CPI	The boy boild furnitie	Thursday is			





Activating the innate, adaptive immune system and correcting the TME





Portage's iNKT Agonist (PORT-2): Rationally Designed Liposomal Formulation of IMM60 iNKT in charged liposome to protect lipid chain, aggregate in tumor, and promote Type 1 cytokine release





Multiple Cell Types Needed for Anti-Cancer Response




PORT-2 compound impacts all these pathways, including changing the tumor directly



# PORT-2 Demonstrates Robust Single Agent Activity





11 Jukes et al Eur. J. Immunol. 2016. 00: 1–11

portage

# ASCO 2023 Data Further Supports PORT-2 Favorable Safety & Tolerability Profile At All Doses Tested to Date



portage

Table 1: Demographics and Baseline Characteristics (n=12)			
Turnor type (%)	Melanoma: 6 (50) NSCLC 6 (50)		
Age (range)	64 (41,79)		
Median prior therapies (range)*	4 (2,7)		
Prior PD-1* (%)	11 (100)		
Performance status (%)	ECOG 0: 8 (67) ECOG 1: 4 (33)		

Table 2: Adverse Events related to IMM60 (n=12)

Grade 2

0

0

0

0

Ü

0

0

0

0

0

0

0

0

1 (8%)

1 (17%)

Grade 3-5

0

0

0

0

0

0

0

0

0

0

0

0

a

0

0

Grade 1

1 (8%)

1 (8%)

2 (17%)

1 (8%)

1 (8%)

1 (8%)

1 (8%)

1 (8%)

1 (8%)

1 (8%)

1 (8%)

1 (8%)


1 (8%)

1 (8%)

0

### Exposure

- · A total of 49 infusions given to 12 patients at doses up to 9 mg/m<sup>2</sup>, with a median of 5 doses per patient
- · Pk shows dose proportionality



### Safety

- · No DLT's, related SAEs, or G3-5 related AEs
- Only G1 related AEs have been observed at the highest dose of PORT-2
- · One patient treated with PORT-2 + pembrolizumab experienced only low-grade AEs consistent with the safety profile of pembrolizumab



Adverse Event

Cough

Diarrhea

Dizziness

Dry mouth

Dyspnea

Fatigue

Hair Loss

Headache

Fever

Nausea

Pruritus

Vomiting


Hypertension

Flu-like symptoms

AST/ALT elevation


ASCO 2023 - Early Evidence of Single Agent Activity for PORT-2 in Advanced Melanoma & NSCLC (IMP-MEL)






- Serum biomarker analyses provide evidence of iNKT, NK, DC activation, as well as increases in antigen-presenting CD86+ B cells following treatment with PORT-2
- Combination with an anti-PD1 antibody is ongoing, with encouraging preliminary reduction in liver lesions observed

 Example patient treated at 3mg/m<sup>2</sup> had mixed response (melanoma patient failed anti-PD-1 and targeted therapy)






Mediastinal Lesion Decreased from 4cm to 1.9cm

 Based on the favorable safety and tolerability data at all doses tested to date, the Phase 1 portion of this trial is expanding to evaluate higher dose levels. Data by end of 2023



IMPORT-201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma



# **Adenosine Portfolio**


Validated mechanism impacting multiple immune cells

Opportunity to modulate adenosine in 4 different ways:

PORT-6 A2AR Inhibitor PORT-7 A2BR Inhibitor PORT-8 A2AR/A2BR Dual Inhibitor PORT-9 Gut-Restricted A2BR Inhibitor








16 Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0



### Difference in A2A Small Molecules

### Portage's PORT-6 is best in class for potency, selectivity and durability




111

### Fast Follower with Precedent for Biomarker Selection Enrich patient population with biomarker/clinical data



Tumors with High Adenosine			
Tumor type	% A2A high*		
RCC	50		
BC	38		
NSCLC	34		
Gastric	32		
Prostate	26		



\* Expression data from Labcorp



11:



High potency and selectivity may provide important safety and efficacy advantages

Activity in 4T1, CT26, and other disease models (asthma, fibrosis, sickle cell)

Function	al Receptor /	Antagonism	Bir	nding Affinity	,
Receptor	Ki (nm)	Selectivity	Receptor	Ki (nm)	Selectivity
A2B	9	1	A2B	13	1
A1	>30,000	>3000x	A1	300	23x
A2A	>10,000	>1000x	A2A	1,800	138x
A3	>30,000	>3000x	A3	60,000	>4,000x

Portage only company developing potent/selective A2B inhibitor


19 Data on File



### ADPORT-601: Adaptive Phase 1a/1b Study



A2AR (PORT-6) indications: Prostate Cancer, Non-small Cell Lung Cancer, Head & Neck Cancer, Renal Cell Cancer with high A2A expression A2BR (PORT-7) indications: Colorectal Cancer, Non-small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer with high A2B expression





portage


### Broad and deep intellectual property covering:

iNKT	Adenosine	Nanolipogel & DNA Aptamers	VLP Delivery
Agonists	Inhibitors		Platform
Composition,     formulations with	Composition of matter     patents	Optimized co-delivery     platforms	<ul> <li>First-in-class systemic STING agonist</li> </ul>
antigens, other I/O agents • Liposomes/particles	Use patents filed	<ul> <li>New IP for aptamers</li> <li>Composition patents for products</li> </ul>	
Many Application		•60	2031-2041
Pending Worldwic		d Patents	Patent Exclusivity





# Key Upcoming Clinical Development Milestones\*





Cash Balance (12/31/22)	~\$13.1 million
Committed Purchase Lincoln Park Capital Available <sup>^</sup>	\$29.8 million
Debt	\$-
Shares Outstanding (03/01/23)**	17,403,594
Insider Ownership	50%
Public Float*	50%
Options & RSUs Outstanding (12/31/22)	1,596,040
Cash Burn During Quarter Ended 12/31/22	\$(~2.0 million)
Expected Quarterly Cash Burn in 2023	~\$5 million

APortage has the right (sole discretion/no obligation), to sell up to \$30 million shares over agreement's 36-month term based on prevailing market prices at the time of each sale, subject to certain conditions. As of 2/28/23, approximately \$28.5 million are are liable proceeds under the Purchase Agreement.
 \*Includes <3.5M Shares subject to lock-up agreements (6-12 mo) in recent 2 stock transactions.</li>
 \*Excludes 4, 127 shares earned for services rendered in January and February 2023, accrued at February 28, 2023 but not yet issued.





portage

